Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Supratherapeutic Elinzanetant
NCT05481528Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elinzanetant in vasomotor symptoms (6 arms), sponsored by Bayer. Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs related to elinzanetant. Started Aug 2022; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05481528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481528.